Clinical trial
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or…
NCT00412828 · CuraGen Corporation, Industry · Completed
Key facts
| NCT number | NCT00412828 |
|---|---|
| Title | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma |
| Official title | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma |
| Lead sponsor | CuraGen Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unresectable Stage III or Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | CR011-vcMMAE |
| Enrollment | 117 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | May 1, 2011 |
| First posted | Dec 19, 2006 |
| Last update posted | Feb 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: